Patents Examined by Marcos L Sznaidman
  • Patent number: 10328082
    Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: June 25, 2019
    Assignee: Pfizer Inc.
    Inventors: Eugene Lvovich Piatnitski Chekler, Adam Matthew Gilbert, Rayomand Jal Unwalla, Patrick Robert Verhoest, James Thomas Anderson
  • Patent number: 10316032
    Abstract: Solid forms of Compound I (and its S-enantiomer, Compound II), active on protein kinases, were prepared and characterized: Also provided are methods of using the solid forms.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: June 11, 2019
    Assignee: Plexxikon Inc.
    Inventors: Prabha N. Ibrahim, Gary Conard Visor
  • Patent number: 10299475
    Abstract: To provide a compound highly active against pests, a pesticide using the compound, and a method for controlling pests by applying the compound. A phenoxyalkylbenzamide compound represented by the formula (I) or its salt; a pesticide containing it as an active ingredient, and a controlling method, which comprises applying an effective amount of the compound: wherein R1, Y and R3 are a hydrogen atom or the like, and Ar is as follows: wherein R4 and R7 are halogen or the like, R5 and R6 are a hydrogen atom or the like, m is from 0 to 5, and n is from 0 to 3.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: May 28, 2019
    Assignee: ISHIHARA SANGYO KAISHA, LTD.
    Inventors: Koji Higuchi, DamdinSuren Boldbaatar, Yuta Tazawa, Michiko Kanuma
  • Patent number: 10294223
    Abstract: Compounds that are Fibroblast Growth Factor Inhibitors (FGFR) and are therefore useful for the treatment of diseases treatable by inhibition of FGFR are disclosed. Also disclosed are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: May 21, 2019
    Assignee: PRINCIPIA BIOPHARMA, INC.
    Inventors: Erik Verner, Kenneth Albert Brameld
  • Patent number: 10292992
    Abstract: This invention provides novel polydentate selective high affinity ligands (SHALs) that can be used in a variety of applications in a manner analogous to the use of antibodies. SHALs typically comprise a multiplicity of ligands that each bind different region son the target molecule. The ligands are joined directly or through a linker thereby forming a polydentate moiety that typically binds the target molecule with high selectivity and avidity.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: May 21, 2019
    Assignees: Lawrence Livermore National Security, LLC, The Regents of the University of California
    Inventors: Sally J. DeNardo, Gerald L. DeNardo, Rodney L. Balhorn
  • Patent number: 10278968
    Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: May 7, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Francesco Parlati, Keith Orford, Sam H. Whiting
  • Patent number: 10278960
    Abstract: The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 7, 2019
    Assignee: Enzo Biochem, Inc.
    Inventors: Elazar Rabbani, James J. Donegan
  • Patent number: 10278932
    Abstract: Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 7, 2019
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Patent number: 10273202
    Abstract: Described herein are nitroxyl progenitor compounds, and compositions including, and methods or generating, the compounds thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: April 30, 2019
    Assignee: The Johns Hopkins University
    Inventors: John P. Toscano, Christopher M. Pavlos, Preeya Kapur Boppana
  • Patent number: 10265280
    Abstract: Formulations for treating ocular surface diseases, such as dry eye disease, and related methods are disclosed. The formulations include ambroxol or a chemical derivative thereof (for example, ambroxol hydrochloride) dispersed in a carrier and may optionally include a biocompatible polymer to provide extended release properties.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: April 23, 2019
    Inventors: Mingwu Wang, Cindy A Wang
  • Patent number: 10226470
    Abstract: Methods are provided for treating autoimmune disease in a subject by inhibiting the activity of DGAT1.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: March 12, 2019
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Kareem Graham, Eugene C. Butcher
  • Patent number: 10221197
    Abstract: The present application provides the compounds of formula (J), or pharmaceutically acceptable salts, isomers, or a mixture thereof, wherein n, m, q, A?, W1, W2, W3, R1, R2, and R3 are described herein. The compounds are inhibitors to the activities of phosphatidylinositol 3-kinase (PI3K) and are useful for treating conditions mediated by one or more PI3K isoforms. The present application further provides pharmaceutical compositions that include a compound of formula (J), or pharmaceutically acceptable salts, isomers, tautomer, or mixture thereof, and methods of using these compounds and compositions for treating conditions mediated by one or more PI3K isoforms.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 5, 2019
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Jerry Evarts, Joshua Kaplan, Musong Kim, Devan Naduthambi, Leena Patel, Stephane Perreault, Barton W. Phillips, Gary Phillips, Kirk L. Stevens, Jennifer A. Treiberg, Joshua Van Veldhuizen, William J. Watkins, Suet Chung Yeung
  • Patent number: 10221161
    Abstract: The present invention provides compounds of formula (I), compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, R12, R13, A, L, B, n, W, X, Y and Z are as defined herein.
    Type: Grant
    Filed: August 14, 2014
    Date of Patent: March 5, 2019
    Assignee: Kalvista Pharmaceuticals Limited
    Inventors: Hannah Joy Edwards, David Michael Evans, Premji Meghani, Andrew Richard Novak
  • Patent number: 10207984
    Abstract: The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein.
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: February 19, 2019
    Assignees: Emory University, Wake Forest University Health Services
    Inventors: Huw M. L. Davies, Spandan Chennamadhavuni, Thomas J. Martin, Steven R. Childers
  • Patent number: 10201507
    Abstract: A composition for treating Fragile X syndrome in a subject in need thereof, wherein the composition includes an effective amount of a modulator of a chloride transporter.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: February 12, 2019
    Assignees: NEUROCHLORE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE AIX MARSEILLE, CENTRE HOSPITALIER UNIVERSITAIRE DE BREST
    Inventors: Yehezkel Ben-Ari, Eric Lemonnier, Nail Burnashev, Roman Tyzio
  • Patent number: 10196381
    Abstract: The present invention relates to a class of benzimidazole-2-piperazine heterocyclic derivatives, a preparation method and medical use thereof. Specifically, the present invention relates to a new benzimidazole-2-piperazine heterocyclic derivative of general Formula (I), a preparation method, a pharmaceutical composition containing the same, and use thereof as a therapeutic agent and especially as a poly(ADP-ribose)polymerase (PARP) inhibitor.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: February 5, 2019
    Assignee: SHANGHAI HUILUN LIFE SCIENCE &TECHNOLOGY CO., LTD
    Inventors: Xing Fan, Jihong Qin
  • Patent number: 10183933
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: January 22, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Anne-Laure Grillot, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Jingrong Cao, Upul Keerthi Bandarage, Suganthini S. Nanthakumar
  • Patent number: 10183015
    Abstract: This disclosure provides compounds and methods of using those compounds to treat liver fibrosis, including liver fibrosis which is a precursor to, is concurrent with, is associated with, or is secondary to nonalcoholic steatohepatitis (NASH); elevated cholesterol levels, and insulin resistance.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: January 22, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha
  • Patent number: 10179767
    Abstract: The invention provides compounds having activity as sodium channel (e.g., NaV1.7) inhibitors that are useful for treating sodium channel-mediated diseases or conditions, such as pain, as well as other diseases and conditions associated with the mediation of sodium channels, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: January 15, 2019
    Assignees: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan Chowdhury, Christoph Martin Dehnhardt, Abid Hasan, Ivan William Hemeon, Qi Jia, Jun Li, Zhiguo Liu, Daniel F. Ortwine, Brian Safina, Daniel Sutherlin, Shaoyi Sun, Andrew D. White, Wei Gong, Alla Yurevna Zenova, Jiuxiang Zhu
  • Patent number: 10179107
    Abstract: The present invention relates to a tablet having a weight of 30-200 mg and consisting of: 60-100 wt. % of granules consisting of: 50-90% by weight of the granules of dehydroepiandrosterone (DHEA); 6-35% by weight of the granules of microcrystalline cellulose; 0-20% by weight of the granules of one or more other pharmaceutically acceptable granule ingredients; and 0-40 wt. % of one or more other pharmaceutically acceptable tablet components. These tablets can suitably be used to orally administer DHEA in dosages of around 50 mg and are sufficiently small to be incorporated in, for instance, ordinary oral contraceptive blister packs.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: January 15, 2019
    Assignee: PANTARHEI BIOSCIENCE B.V.
    Inventors: Herman Jan Tijmen Coelingh Bennink, Johannes Jan Platteeuw